TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

NCT02493530 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis
Polycythemia Vera

Interventions

DRUG: TGR-1202
DRUG: ruxolitinib

Sponsor

Vanderbilt-Ingram Cancer Center